Nuclear IKKα mediates microRNA-7/-103/107/21 inductions to downregulate maspin expression in response to HBx overexpression

Oncotarget

Volumn 7, Issue 35, 2016, Pages 56309-56323

  Chen, Wen Shu ^a,b,c   Liu, Liang Chih ^b,d   Yen, Chia Jui ^e   Chen, Yun Ju ^f,g   Chen, Jhen Yu ^b,c   Ho, Chien Yi ^b   Liu, Shu Hui ^h   Chen, Ching Chow ^a   Huang, Wei Chien ^b,c,i  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

^e NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^f E DA HOSPITAL   (Taiwan)

^g I SHOU UNIVERSITY   (Taiwan)

^h YU DA UNIVERSITY   (Taiwan)

ⁱ ASIA UNIVERSITY   (Taiwan)

Author keywords

HBx; Hepatocellular carcinoma; IKK ; Maspin; MicroRNA

Indexed keywords

HEPATITIS B VIRUS X PROTEIN; HISTONE H3; I KAPPA B KINASE ALPHA; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MASPIN; MESSENGER RNA; MICRORNA; MICRORNA 103; MICRORNA 107; MICRORNA 21; MICRORNA 7; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; CHUK PROTEIN, HUMAN; HISTONE; I KAPPA B KINASE; IKBKB PROTEIN, HUMAN; SERINE PROTEINASE INHIBITOR; SERPIN-B5; TRANSACTIVATOR PROTEIN; TUMOR MARKER;

3' UNTRANSLATED REGION; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CELL VIABILITY; CELLULAR DISTRIBUTION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DOWN REGULATION; DRUG RESISTANCE; EPIGENETICS; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; HEPATITIS B; HEPATOCELLULAR CARCINOMA CELL LINE; HUMAN; HUMAN TISSUE; MOLECULAR DYNAMICS; MTT ASSAY; PROMOTER REGION; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RNA STABILITY; RNA TRANSLATION; TRANSCRIPTION INITIATION; TRANSCRIPTION INITIATION SITE; TRANSCRIPTION REGULATION; UPREGULATION; APOPTOSIS; CARCINOGENESIS; CELL NUCLEUS; DISEASE EXACERBATION; GENETICS; HEK293 CELL LINE; HEPATITIS B VIRUS; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE; VIROLOGY;

APOPTOSIS; BIOMARKERS, TUMOR; CARCINOGENESIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL NUCLEUS; DISEASE PROGRESSION; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HEK293 CELLS; HEPATITIS B VIRUS; HISTONES; HUMANS; I-KAPPA B KINASE; LIVER NEOPLASMS; MICRORNAS; PHOSPHORYLATION; RNA, MESSENGER; SERPINS; SIGNAL TRANSDUCTION; TRANS-ACTIVATORS;

EID: 84984879064     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.10462     Document Type: Article

References (71)

1. Lara-Pezzi E, Gomez-Gaviro MV, Galvez BG, Mira E, Iniguez MA, Fresno M, Martinez AC, Arroyo AG and Lopez-Cabrera M. The hepatitis B virus X protein promotes tumor cell invasion by inducing membrane-type matrix metalloproteinase-1 and cyclooxygenase-2 expression. The Journal of clinical investigation. 2002; 110:1831-1838.
2. Lee JO, Lee KW, Oh DY, Kim JH, Im SA, Kim TY and Bang YJ. Combination chemotherapy with capecitabine and cisplatin for patients with metastatic hepatocellular carcinoma. Annals of oncology. 2009; 20:1402-1407.
3. Anwar WA, Khaled HM, Amra HA, El-Nezami H and Loffredo CA. Changing pattern of hepatocellular carcinoma (HCC) and its risk factors in Egypt: possibilities for prevention. Mutation research. 2008; 659:176-184.
4. Parkin DM, Bray F, Ferlay J and Pisani P. Estimating the world cancer burden: Globocan 2000. International Journal of Cancer. 2001; 94:153-156.
5. Bartosch B. Hepatitis B and C viruses and hepatocellular carcinoma. Viruses. 2010; 2:1504-1509.
6. Fink SA and Jacobson IM. Managing patients with hepatitisB-related or hepatitisC-related decompensated cirrhosis. Nature reviews Gastroenterology & hepatology. 2011; 8:285-295.
7. McGlynn KA and London WT. Epidemiology and natural history of hepatocellular carcinoma. Best practice & research Clinical gastroenterology. 2005; 19:3-23.
8. Ali A, Abdel-Hafiz H, Suhail M, Al-Mars A, Zakaria MK, Fatima K, Ahmad S, Azhar E, Chaudhary A and Qadri I. Hepatitis B virus, HBx mutants and their role in hepatocellular carcinoma. World journal of gastroenterology. 2014; 20:10238-10248.
9. Huang WC, Hsieh YL, Hung CM, Chien PH, Chien YF, Chen LC, Tu CY, Chen CH, Hsu SC, Lin YM and Chen YJ. BCRP/ABCG2 inhibition sensitizes hepatocellular carcinoma cells to sorafenib. PloS one. 2013; 8:e83627.
10. Mai L, Yang L, Kuang JY, Zhu JY, Kang YH, Zhang FC, Xie QF and Gao ZL. [Hepatitis B virus X promotes HepG2 cell cycle progression and growth via downregulation expression of p16 protein]. [Article in Chinese]. Zhonghua gan zang bing za zhi. 2013; 21:614-618.
11. Wang HY, Yang SL, Liang HF and Li CH. HBx protein promotes oval cell proliferation by up-regulation of cyclin D1 via activation of the MEK/ERK and PI3K/Akt pathways. International journal of molecular sciences. 2014; 15:3507-3518.
12. Khattar E, Mukherji A and Kumar V. Akt augments the oncogenic potential of the HBx protein of hepatitis B virus by phosphorylation. The FEBS journal. 2012; 279:1220-1230.
13. Chen X, Zhang L, Zheng S, Zhang T, Li M, Zhang X, Zeng Z, McCrae MA, Zhao J, Zhuang H and Lu F. Hepatitis B Virus X Protein Stabilizes Cyclin D1 and Increases Cyclin D1 Nuclear Accumulation through ERK-Mediated Inactivation of GSK-3beta. Cancer prevention research. 2015; 8:455-463.
14. Chung TW, Lee YC and Kim CH. Hepatitis B viral HBx induces matrix metalloproteinase-9 gene expression through activation of ERK and PI-3K/AKT pathways: involvement of invasive potential. FASEB journal. 2004; 18:1123-1125.
15. Lee JO, Kwun HJ, Jung JK, Choi KH, Min DS and Jang KL. Hepatitis B virus X protein represses E-cadherin expression via activation of DNA methyltransferase 1. Oncogene. 2005; 24:6617-6625.
16. Zhang X, Liu S, Hu T, Liu S, He Y and Sun S. Up-regulated microRNA-143 transcribed by nuclear factor kappa B enhances hepatocarcinoma metastasis by repressing fibronectin expression. Hepatology. 2009; 50:490-499.
17. Li C, Sun Y, Geng L and Fan F. [HBx silencing by shRNA down-regulates MMP-2 expression in human hepatocellular carcinoma cell HepG2.2.15]. [Article in Chinese]. Xi bao yu fen zi mian yi xue za zhi. 2014; 30:371-374.
18. Yu FL, Liu HJ, Lee JW, Liao MH and Shih WL. Hepatitis B virus X protein promotes cell migration by inducing matrix metalloproteinase-3. Journal of hepatology. 2005; 42:520-527.
19. Kapoor NR, Ahuja R, Shukla SK and Kumar V. The HBx protein of hepatitis B virus confers resistance against nucleolar stress and anti-cancer drug-induced p53 expression. FEBS letters. 2013; 587:1287-1292.
20. Gottlob K, Fulco M, Levrero M and Graessmann A. The hepatitis B virus HBx protein inhibits caspase 3 activity. The Journal of biological chemistry. 1998; 273:33347-33353.
21. Kuo TC and Chao CC. Hepatitis B virus X protein prevents apoptosis of hepatocellular carcinoma cells by upregulating SATB1 and HURP expression. Biochemical pharmacology. 2010; 80:1093-1102.
22. Zhu H, Luo SF, Wang J, Li X, Wang H, Pu WY, Zhang H and Zhuang ZX. Effect of environmental factors on chemoresistance of HepG2 cells by regulating hypoxiainducible factor-1alpha. Chinese medical journal. 2012; 125:1095-1103.
23. Cheng AS, Wong N, Tse AM, Chan KY, Chan KK, Sung JJ and Chan HL. RNA interference targeting HBx suppresses tumor growth and enhances cisplatin chemosensitivity in human hepatocellular carcinoma. Cancer letters. 2007; 253:43-52.
24. He Y, Sun HQ, He XE, Wang WL and Lei JH. Knockdown of HBx by RNAi inhibits proliferation and enhances chemotherapy-induced apoptosis in hepatocellular carcinoma cells. Medical oncology. 2010; 27:1227-1233.
25. Kim HY, Jung HU, Yoo SH, Yoo KS, Cheong J, Park BS, Yun I and Yoo YH. Sorafenib overcomes the chemoresistance in HBx-expressing hepatocellular carcinoma cells through down-regulation of HBx protein stability and suppresses HBV gene expression. Cancer letters. 2014; 355:61-69.
26. Tan YL and Chen WN. MicroRNAs as therapeutic strategy for hepatitis B virus-associated hepatocellular carcinoma: current status and future prospects. World journal of gastroenterology. 2014; 20:5973-5986.
27. Lamontagne J, Steel LF and Bouchard MJ. Hepatitis B virus and microRNAs: Complex interactions affecting hepatitis B virus replication and hepatitis B virus-associated diseases. World journal of gastroenterology. 2015; 21:7375-7399.
28. Chen WS, Yen CJ, Chen YJ, Chen JY, Wang LY, Chiu SJ, Shih WL, Ho CY, Wei TT, Pan HL, Chien PH, Hung MC, Chen CC and Huang WC. miRNA-7/21/107 contribute to HBx-induced hepatocellular carcinoma progression through suppression of maspin. Oncotarget. 2015; 6:25962-25974. doi: 10.18632/oncotarget.4504.
29. Ruland J. Return to homeostasis: downregulation of NF-kappaB responses. Nature immunology. 2011; 12:709-714.
30. Jiang R, Xia Y, Li J, Deng L, Zhao L, Shi J, Wang X and Sun B. High expression levels of IKKalpha and IKKbeta are necessary for the malignant properties of liver cancer. International journal of cancer. 2010; 126:1263-1274.
31. Marquardt JU, Gomez-Quiroz L, Arreguin Camacho LO, Pinna F, Lee YH, Kitade M, Dominguez MP, Castven D, Breuhahn K, Conner EA, Galle PR, Andersen JB, Factor VM and Thorgeirsson SS. Curcumin effectively inhibits oncogenic NF-κB signaling and restrains stemness features in liver cancer. Journal of hepatology. 2015.
32. Kew MC. Hepatitis B virus x protein in the pathogenesis of hepatitis B virus-induced hepatocellular carcinoma. Journal of gastroenterology and hepatology. 2011; 26 Suppl 1:144-152.
33. Huang WC, Chen WS, Chen YJ, Wang LY, Hsu SC, Chen CC and Hung MC. Hepatitis B virus X protein induces IKKalpha nuclear translocation via Akt-dependent phosphorylation to promote the motility of hepatocarcinoma cells. Journal of cellular physiology. 2012; 227:1446-1454.
34. Luo JL, Tan W, Ricono JM, Korchynskyi O, Zhang M, Gonias SL, Cheresh DA and Karin M. Nuclear cytokineactivated IKKalpha controls prostate cancer metastasis by repressing Maspin. Nature. 2007; 446:690-694.
35. Yamamoto Y, Verma UN, Prajapati S, Kwak YT and Gaynor RB. Histone H3 phosphorylation by IKK-alpha is critical for cytokine-induced gene expression. Nature. 2003; 423:655-659.
36. Yoshida K, Ozaki T, Furuya K, Nakanishi M, Kikuchi H, Yamamoto H, Ono S, Koda T, Omura K and Nakagawara A. ATM-dependent nuclear accumulation of IKK-alpha plays an important role in the regulation of p73-mediated apoptosis in response to cisplatin. Oncogene. 2008; 27:1183-1188.
37. Fernandez-Majada V, Aguilera C, Villanueva A, Vilardell F, Robert-Moreno A, Aytes A, Real FX, Capella G, Mayo MW, Espinosa L and Bigas A. Nuclear IKK activity leads to dysregulated notch-dependent gene expression in colorectal cancer. Proceedings of the National Academy of Sciences of the United States of America. 2007; 104:276-281.
38. Nowak SJ and Corces VG. Phosphorylation of histone H3: a balancing act between chromosome condensation and transcriptional activation. Trends in genetics. 2004; 20:214-220.
39. Huang WC, Ju TK, Hung MC and Chen CC. Phosphorylation of CBP by IKKalpha promotes cell growth by switching the binding preference of CBP from p53 to NF-kappaB. Molecular cell. 2007; 26:75-87.
40. Burden HE and Weng Z. Identification of conserved structural features at sequentially degenerate locations in transcription factor binding sites. Genome informatics International Conference on Genome Informatics. 2005; 16:49-58.
41. Sandelin A, Alkema W, Engstrom P, Wasserman WW and Lenhard B. JASPAR: an open-access database for eukaryotic transcription factor binding profiles. Nucleic acids research. 2004; 32:D91-94.
42. Tsunoda T and Takagi T. Estimating transcription factor bindability on DNA. Bioinformatics. 1999; 15:622-630.
43. Perez-Cadahia B, Drobic B and Davie JR. H3 phosphorylation: dual role in mitosis and interphase. Biochemistry and cell biology = Biochimie et biologie cellulaire. 2009; 87:695-709.
44. Allavena P, Garlanda C, Borrello MG, Sica A and Mantovani A. Pathways connecting inflammation and cancer. Current opinion in genetics & development. 2008; 18:3-10.
45. Sun B and Karin M. NF-kappaB signaling, liver disease and hepatoprotective agents. Oncogene. 2008; 27:6228-6244.
46. Hacker H and Karin M. Regulation and function of IKK and IKK-related kinases. Science's STKE. 2006; 2006:re13.
47. Scheidereit C. IkappaB kinase complexes: gateways to NF-kappaB activation and transcription. Oncogene. 2006; 25:6685-6705.
48. Sheng S, Carey J, Seftor EA, Dias L, Hendrix MJ and Sager R. Maspin acts at the cell membrane to inhibit invasion and motility of mammary and prostatic cancer cells. Proceedings of the National Academy of Sciences of the United States of America. 1996; 93:11669-11674.
49. Zhang M, Volpert O, Shi YH and Bouck N. Maspin is an angiogenesis inhibitor. Nature medicine. 2000; 6:196-199.
50. Jiang N, Meng Y, Zhang S, Mensah-Osman E and Sheng S. Maspin sensitizes breast carcinoma cells to induced apoptosis. Oncogene. 2002; 21:4089-4098.
51. Bodenstine TM, Seftor RE, Khalkhali-Ellis Z, Seftor EA, Pemberton PA and Hendrix MJ. Maspin: molecular mechanisms and therapeutic implications. Cancer metastasis reviews. 2012; 31:529-551.
52. Maass N, Biallek M, Rosel F, Schem C, Ohike N, Zhang M, Jonat W and Nagasaki K. Hypermethylation and histone deacetylation lead to silencing of the maspin gene in human breast cancer. Biochemical and biophysical research communications. 2002; 297:125-128.
53. Futscher BW, Oshiro MM, Wozniak RJ, Holtan N, Hanigan CL, Duan H and Domann FE. Role for DNA methylation in the control of cell type specific maspin expression. Nature genetics. 2002; 31:175-179.
54. Liao XH, Li YQ, Wang N, Zheng L, Xing WJ, Zhao DW, Yan TB, Wang Y, Liu LY, Sun XG, Hu P, Zhou H and Zhang TC. Re-expression and epigenetic modification of maspin induced apoptosis in MCF-7 cells mediated by myocardin. Cellular signalling. 2014; 26:1335-1346.
55. Liu LN, Li DD, Xu HX, Zheng SG and Zhang XP. Role of microRNAs in hepatocellular carcinoma. Frontiers in bioscience. 2015; 20:1056-1067.
56. Srivastava SK, Arora S, Averett C, Singh S and Singh AP. Modulation of microRNAs by phytochemicals in cancer: underlying mechanisms and translational significance. BioMed research international. 2015; 2015:848710.
57. Neelakandan K, Babu P and Nair S. Emerging roles for modulation of microRNA signatures in cancer chemoprevention. Current cancer drug targets. 2012; 12:716-740.
58. Yu Z, Ni L, Chen D, Zhang Q, Su Z, Wang Y, Yu W, Wu X, Ye J, Yang S, Lai Y and Li X. Identification of miR-7 as an oncogene in renal cell carcinoma. Journal of molecular histology. 2013; 44:669-677.
59. Hao Z, Yang J, Wang C, Li Y, Zhang Y, Dong X, Zhou L, Liu J, Zhang Y and Qian J. MicroRNA-7 inhibits metastasis and invasion through targeting focal adhesion kinase in cervical cancer. International journal of clinical and experimental medicine. 2015; 8:480-487.
60. Tu CY, Chen CH, Hsia TC, Hsu MH, Wei YL, Yu MC, Chen WS, Hsu KW, Yeh MH, Liu LC, Chen YJ and Huang WC. Trichostatin A suppresses EGFR expression through induction of microRNA-7 in an HDAC-independent manner in lapatinib-treated cells. BioMed research international. 2014; 2014:168949.
61. Hsia TC, Tu CY, Chen YJ, Wei YL, Yu MC, Hsu SC, Tsai SL, Chen WS, Yeh MH, Yen CJ, Yu YL, Huang TC, Huang CY, Hung MC and Huang WC. Lapatinib-mediated cyclooxygenase-2 expression via epidermal growth factor receptor/HuR interaction enhances the aggressiveness of triple-negative breast cancer cells. Molecular pharmacology. 2013; 83:857-869.
62. Chen YJ, Yeh MH, Yu MC, Wei YL, Chen WS, Chen JY, Shih CY, Tu CY, Chen CH, Hsia TC, Chien PH, Liu SH, Yu YL and Huang WC. Lapatinib-induced NF-kappaB activation sensitizes triple-negative breast cancer cells to proteasome inhibitors. Breast cancer research. 2013; 15:R108.
63. Chen YJ, Chien PH, Chen WS, Chien YF, Hsu YY, Wang LY, Chen JY, Lin CW, Huang TC, Yu YL and Huang WC. Hepatitis B Virus-Encoded X Protein Downregulates EGFR Expression via Inducing MicroRNA-7 in Hepatocellular Carcinoma Cells. Evidence-based complementary and alternative medicine. 2013; 2013:682380.
64. Sheth S, Jajoo S, Kaur T, Mukherjea D, Sheehan K, Rybak LP and Ramkumar V. Resveratrol reduces prostate cancer growth and metastasis by inhibiting the Akt/MicroRNA-21 pathway. PloS one. 2012; 7:e51655.
65. Kleivi Sahlberg K, Bottai G, Naume B, Burwinkel B, Calin GA, Borresen-Dale AL and Santarpia L. A serum microRNA signature predicts tumor relapse and survival in triple-negative breast cancer patients. Clinical cancer research. 2015; 21:1207-1214.
66. Zhang Y, Qu X, Li C, Fan Y, Che X, Wang X, Cai Y, Hu X and Liu Y. miR-103/107 modulates multidrug resistance in human gastric carcinoma by downregulating Cav-1. Tumour biology. 2015; 36:2277-2285.
67. Huang JW, Wang Y, Dhillon KK, Calses P, Villegas E, Mitchell PS, Tewari M, Kemp CJ and Taniguchi T. Systematic screen identifies miRNAs that target RAD51 and RAD51D to enhance chemosensitivity. Molecular cancer research. 2013; 11:1564-1573.
68. Liu B, Sun L, Liu Q, Gong C, Yao Y, Lv X, Lin L, Yao H, Su F, Li D, Zeng M and Song E. A cytoplasmic NF-kappaB interacting long noncoding RNA blocks IkappaB phosphorylation and suppresses breast cancer metastasis. Cancer cell. 2015; 27:370-381.
69. Hsiao YC, Yeh MH, Chen YJ, Liu JF, Tang CH and Huang WC. Lapatinib increases motility of triple-negative breast cancer cells by decreasing miRNA-7 and inducing Raf-1/MAPK-dependent interleukin-6. Oncotarget. 2015; 6:37965-37978. doi: 10.18632/oncotarget.5700.
70. Chen JY, Chen YJ, Yen CJ, Chen WS and Huang WC. HBx sensitizes hepatocellular carcinoma cells to lapatinib by up-regulating ErbB3. Oncotarget. 2016; 7:473-89. doi: 10.18632/oncotarget.6337.
71. Huang WC, Hsu SC, Huang SJ, Chen YJ, Hsiao YC, Zhang W, Fidler IJ and Hung MC. Exogenous expression of human SGLT1 exhibits aggregations in sodium dodecyl sulfate polyacrylamide gel electrophoresis. American journal of translational research. 2013; 5:441-449.